symbiotics sa presentation
play

Symbiotics SA Presentation Roland Dominic, CEO Pushing money to - PowerPoint PPT Presentation

Apr 16, 2023 •244 likes •449 views

Symbiotics SA Presentation Roland Dominic, CEO Pushing money to where it normally doesnt flow 2 The leading market access platform for impact investing Research (market studies, due diligences, ratings, publications) Deals

  1. Symbiotics SA Presentation Roland Dominicé, CEO

  2. “Pushing money to where it normally doesn’t flow” 2

  3. The leading market access platform for impact investing ▪ Research (market studies, due diligences, ratings, publications) ▪ Deals (brokerage, plumseeds.com) ▪ Mandates (advisory, discretionary, DFI) ▪ Funds (private debt, impact bonds, private equity) ▪ Impact (capacity building, social performance, impact measurement) 3

  4. Track record ▪ > 4000 transactions ▪ Since December 2004 ▪ 150 employees ▪ > USD 5 billion of investments ▪ > 30 nationalities ▪ > USD 2 billion AuM ▪ 8 offices ▪ < 1.0% loss rate ▪ FINMA asset manager ▪ 80 emerging markets ▪ FCA financial adviser ▪ 1000 financial institutions ▪ AFM light broker ▪ 300 investees ▪ 2 million small loans 4

  5. Market Coverage Current investments 2012 2015 2018 CAGR Origination (m$) 302 473 786 17% Since inception Portfolio (m$) 530 1,085 2,014 25% Deals 487 832 1,105 15% Countries 43 55 71 9% Institutions 132 193 274 13% End-clients 788k 1,390k 1,819k 15% Average loan ($) 672 780 1,107 9% Offices 4 6 8 12% Staff 42 83 144 23% 5 Average 16%

  6. Historical clientele 6

  7. investment strategy 7

  8. SDG Integration Household finance (60% AuM): SDG 1, 5, 10 ▪ Commercial banks ▪ Microfinance or mono-thematic institutions ▪ « Fintech » newcomers Small Business Finance (30% AuM): SDG 8, 12 ▪ Specialized SME banks ▪ Specialized or mono-thematic NBFIs ▪ SME investment funds Project & Enterprise Development (10% AuM ) ▪ Agricultural finance (SDG 2) ▪ Community development (SDG 6, 9, 11) ▪ Health & education (SDG 3, 4) ▪ Renewable energy (SDG 7, 14, 15) 8

  9. risk / return 9

  10. Long term absolute performance SMX index since inception, maximum drawdown of -0,35% 170 1,4% 160 1,2% 150 1,0% 140 0,8% Monthly performance 130 0,6% Index value 120 0,4% 110 0,2% 100 0,0% 90 -0,2% 80 -0,4% Dec/03 Dec/04 Dec/05 Dec/06 Dec/07 Dec/08 Dec/09 Dec/10 Dec/11 Dec/12 Dec/13 Dec/14 Dec/15 Dec/16 Dec/17 Dec/18 Monthly performance Index value The SMX index composed of microfinance funds with a monthly NAV and systematic hedge of local currencies. USD after costs 10

  11. Comparative performances 225 200 175 150 125 100 75 50 Dec-03 Dec-04 Dec-05 Dec-06 Dec-07 Dec-08 Dec-09 Dec-10 Dec-11 Dec-12 Dec-13 Dec-14 Dec-15 Dec-16 Dec-17 Dec-18 JPM GBI - Developed markets MSCI World Index SMX MIV Debt USD (after costs) Libor 3 Months USD HFRX Global Hedge Fund Index Bloomberg Commodity Index 11

  12. Volatility and correlations Correlation with Annual volatility of the SMX MIV Debt Index asset class Cash 0.55 0.50% Bonds 0.06 2.98% Stocks -0.10 14.42% Hedge funds -0.14 5.38% Commodities -0.01 16.27% SMX index 1.00 0.56% 12

  13. Comparative performances (2018) 110 105 100 95 90 85 80 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 JPM Hedged USD GBI Global MSCI World Index SMX MIV Debt USD Libor 3 Months USD HFRX Global Hedge Fund Index Bloomberg Commodity Index MSCI Emerging Market 13

  14. 14 brokerage

  15. Plumseeds

  16. market research 16

  17. Publications 1. Why microfinance matters to investors 2. Private debt impact funds (GIIN) 3. 10-year MIV study (CGAP) 4. Banking for Impact 5. Measuring and managing social performance

  18. Thank you www.symbioticsgroup.com 18

  19. Disclaimer This document has been issued by Symbiotics SA (registered office 31 rue de la Synagogue, 1204 Geneva Switzerland). This document contains a preliminary summary of Symbiotics ’ financial activities and products. This document is meant for information purposes only, it cannot constitute an offering or solicitation in any investment products or services offered by Symbiotics. Charts, tables and graphs contained in this document are not intended to be used to assist the reader in determining which securities to buy or sell or when to buy or sell securities. This communication is for the use of intended recipients only and the contents may not be reproduced, redistributed or copied in whole or in part for any purpose without Symbiotics ’ prior express consent. All sources are Symbiotics SA unless otherwise stated. It is the responsibility of potential investors to personally inform themselves and to ensure that their possible participation in the investment possibilities complies with any laws and regulations in the jurisdiction applicable to them, this including the acquisition of any governmental or other authorization as well as the observance of any other formalities prescribed by these jurisdictions. This presentation is addressed to informed and qualified investors possessing the expertise, experience and necessary knowledge to adequately assess and appreciate an impact investment, the accrued risks and the absence of liquidity associated with this type of activities and investment. Investments in any financial product described in this document might bear a higher risk than investments in more developed markets or countries.An investment in securities contains risks, including the risk of loss of the amount invested. 19

Recommend

More recommend